Jeffrey Jones
Chief Medical Officer Cullinan Therapeutics
Seminars
Wednesday 25th March 2026
Panel Discussion: Defining Patient Populations for B-Cell Depletion Therapies & Establishing a ‘Window of Opportunity’ for Treatment
4:30 pm
- Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
- Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
- Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population
Wednesday 25th March 2026
Fireside Chat: Effectively Operationalizing Clinical Trials in Immune Resetting Therapeutics
4:00 pm
- Securing Centre’s of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
- Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
- Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible
